Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis

Conclusion: Although NICE shows a degree of flexibility and pragmatism toward uncertainties in the evidence base for rare disease medicines, this is often off-set by a lengthy appraisal process, which can lead to delays in patients receiving vital treatment.PMID:37724717 | DOI:10.57264/cer-2023-0093
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Source Type: research